Plk1 phosphorylation of Topors is involved in its degradation

被引:8
|
作者
Yang, Xiaoming [1 ,2 ]
Li, Hongchang [1 ]
Deng, Anping [2 ]
Liu, Xiaoqi [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
[2] Sichuan Univ, Coll Chem, Chengdu 610064, Peoples R China
关键词
Topors; Protein degradation; Spindle checkpoint; Polo-like kinase 1; Phosphorylation; TOPOISOMERASE-I-BINDING; RING FINGER PROTEIN; TUMOR-SUPPRESSOR; P53; STABILITY; CELLS;
D O I
10.1007/s11033-009-9871-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topors is a DNA topoisomerase I- and p53-binding protein, and mainly functions as a p53 regulator. Accumulating evidence also supports the notion that Topors plays the role as a negative regulator of cell growth, and possibly as a tumor suppressor. Here, we demonstrated that Topors is also involved in normal mitotic progression, since Topors depletion delays mitotic entry and affects mitotic progression. Furthermore, Topors is degradated in response to the activation of the spindle checkpoint. Significantly, Polo-like kinase 1 (Plk1)-associated phosphorylation of Topors at S718 is essential for nocodazole-induced degradation of Topors.
引用
收藏
页码:3023 / 3028
页数:6
相关论文
共 50 条
  • [41] AMBRA1 phosphorylation by CDK1 and PLK1 regulates mitotic spindle orientation
    Fiorella Faienza
    Federica Polverino
    Girish Rajendraprasad
    Giacomo Milletti
    Zehan Hu
    Barbara Colella
    Deborah Gargano
    Flavie Strappazzon
    Salvatore Rizza
    Mette Vixø Vistesen
    Yonglun Luo
    Manuela Antonioli
    Valentina Cianfanelli
    Caterina Ferraina
    Gian Maria Fimia
    Giuseppe Filomeni
    Daniela De Zio
    Joern Dengjel
    Marin Barisic
    Giulia Guarguaglini
    Sabrina Di Bartolomeo
    Francesco Cecconi
    Cellular and Molecular Life Sciences, 2023, 80
  • [43] The toxicity of dysregulated Plk1 activity revealed by its suppressor mutations
    Kamakura, Nana
    Takahashi, Motoko
    Jo, Minji
    GENES TO CELLS, 2023, 28 (07) : 503 - 515
  • [44] The effect of deuterated PLK1 inhibitor on its safety and efficacy in vivo
    Zhang, Tingyan
    Deng, Xiaobing
    Jin, Haoping
    Peng, Zhengshu
    Hsueh, Yi-Ching
    Zhang, Chunming
    Niu, Gang
    Yang, Jianfei
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [45] DNA-PKcs Associates With PLK1 and Is Involved in Proper Chromosome Segregation and Cytokinesis
    Huang, Bo
    Shang, Zeng-Fu
    Li, Bing
    Wang, Yu
    Liu, Xiao-Dan
    Zhang, Shi-Meng
    Guan, Hua
    Rang, Wei-Qing
    Hu, Jian-An
    Zhou, Ping-Kun
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2014, 115 (06) : 1077 - 1088
  • [46] Cullin' PLK1 from kinetochores
    Colleen A. McGourty
    Michael Rape
    Nature Cell Biology, 2013, 15 : 347 - 348
  • [47] Plk1 in Asthma: Ready for Primetime?
    Tam, John Kit Chung
    Tran, Thai
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2022, 66 (02) : 124 - 125
  • [48] PLK1 AS A THERAPEUTIC TARGET IN ATRT
    Alimova, Irina
    Pierce, Angela M.
    Venkataraman, Sujatha
    Harris, Peter
    Birks, Diane K.
    Amani, Vladimir M.
    Prince, Eric
    Balakrishnan, Ilango
    Foreman, Nicholas K.
    Vibhakar, Rajeev
    NEURO-ONCOLOGY, 2016, 18 : 2 - 2
  • [49] Targeting Plk1 for cancer therapy
    Schmidt, Mathias
    Hofmann, Hans-Peter
    Sanders, Karl
    Gekeler, Volker
    Beckers, Thomas
    EJC SUPPLEMENTS, 2006, 4 (06): : 16 - 16
  • [50] Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy
    Shin, Sol-Bi
    Woo, Sang-Uk
    Lee, Young-Joo
    Yim, Hyungshin
    ANTICANCER RESEARCH, 2017, 37 (03) : 1177 - 1183